SPX

10.0%

1.1¢ spenda limited

Ann: Lending and Payments Volumes Update, page-39

First 39 Last

Share
Profile

Follow
SuperTrumpy

6,702 Posts.

1078

28/06/23

14:51

Post #: 68515115
Share

Originally posted by CDO22: ↑

Let's try to estimate the June 4C:
- Lending: Amount drawn from DW went from $11mio to $13mio. Let's use $12mio average across 3 months. That implies $13.33 portfolio and gross revenues of $0.7mio for that quarter. Cost of fund using 10% would be $0.3mio. They also had a residual position on balance sheet, for $0.7mio. Assuming the same return of 21%, that's another $0.04mio at no cost.
- Payments: Based on the first 2 months of this quarter, I'll assume $45mio for the quarter. Total guess here, but I will use 1% fee on this and no costs. So that's $0.45mio.
- Saas: Only known info is about the Capricorn trial, and I will be optimistic here, assuming the 2 payments will make it this quarter. That's $0.3mio in the bank.
- Total top line revenues: $1.49mio, and $1.19mio net of cost of funds.
- Operational costs: I will assume they have increased by the fee paid for CR, so $2.6mio (from prior quarters), plus 6% x $3.9mio, so total $2.83mio.
- Net result is down $1.64mio.
- Cash position: $4.7+$3.9-$1.64-$0.2 (DW first loss)= $6.76mio.
- Runway = $6.76mio / $1.64 = 4.1 quarters.
Let's see if I am anywhere close! It is likely to be wrong, but the point of this is then to go back and understand why. If the actual result is close, my conclusions would be:
- Payment revenues uplift is very welcome and the company should do a far better job at reporting the associated revenues.
- Saas revenues are not recurring, absent an announcement about Capricorn (which then would make much of this analysis possibly obsolete...).
- With the $ in the bank, there is a path from here towards CF+. It's a tough one though would target something like $40mio lending book and 30% payment volumes increase QoQ. This is what I'd like to hear from the company, quantified targets in terms of each of their revenue streams.
- It would be good to know whether we can expect another R&D refund in FY24.

Expand

I have read that an r&d payment will be received this quarter.

SPX Price at posting: 0.8¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 79 more messages in this thread...

First 39 Last

Add SPX (ASX) to my watchlist

(20min delay)
Last 1.1¢		Change 0.001(10.0%)		Mkt cap ! $50.63M

Open	High	Low	Value	Volume
1.1¢	1.1¢	1.0¢	$79.14K	7.677M

Buyers (Bids)

No.	Vol.	Price($)
8	2615830	1.0¢

Sellers (Offers)

Price($)	Vol.	No.
1.1¢	127186	1

View Market Depth

No.	Vol.	Price($)
8	2615830	0.010
16	5981949	0.009
11	6858248	0.008
6	6232562	0.007
7	3097420	0.006

Price($)	Vol.	No.
0.011	127186	1
0.012	7828806	16
0.013	9242645	10
0.014	8389378	13
0.015	7363083	7

Last trade - 16.10pm 04/10/2024 (20 minute delay)

SPX (ASX) Chart

Ann: Lending and Payments Volumes Update, page-39

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Lending and Payments Volumes Update, page-39

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News